Stock Screener App

無料 -

インストール

79.18

3.17% 2.43

after-market

アフターアワーズ： 79.99 0.81 +1.02%

Kiniksa Pharmaceuticals International Plc (KNSA)

概要ニュース株価時系列オプションチェーン Financials ディスカッション予測

Kiniksa Pharmaceuticals International Plc (KNSA) 最新ニュース

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N - TradingView

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 - Yahoo Finance

KNSA: ARCALYST drives record growth as pipeline advances and patient access, awareness, and satisfaction rise - TradingView

Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Promising Outlook with 28% Potential Upside - DirectorsTalk Interviews

Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (NASDAQ:KNSA) - TradingView

Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)? - simplywall.st

Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by The Manufacturers Life Insurance Company - MarketBeat

Kiniksa Pharmaceuticals to present at Canaccord Genuity Growth Conference on August 12, 2026 - Pluang

Kiniksa’s Aug. 12 fireside chat will stream live online - Stock Titan

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - GlobeNewswire

Kiniksa Pharmaceuticals International PLC (KNSA) Stock News Today - TradingKey

Kiniksa Pharmaceuticals International PLC (KNSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Lazard Asset Management LLC - MarketBeat

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

31,391 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by Financial Enhancement Group LLC - MarketBeat

Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Janus Henderson Group PLC - MarketBeat

Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Strong Earnings Are Of Good Quality - 富途牛牛

Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Unlocking A 33.5% Upside Potential - DirectorsTalk Interviews

Dimensional Fund Advisors LP Purchases 128,417 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook - The Globe and Mail

Kiniksa Pharmaceuticals International, plc (KNSA) director sells and gifts shares - Stock Titan

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director G Bradley Cole Sells 3,673 Shares of Stock - MarketBeat

The Goldman Sachs Group Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price - MarketBeat

KNSA Maintained by Canaccord Genuity -- Price Target Raised to $98 - GuruFocus

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $107.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $98.00 - MarketBeat

Kiniksa Pharmaceuticals International, plc Stock 12‑Month Price Target Raised to $79.62, Implies 25% Upside - TradingView

Stronger Q2 Results And Higher 2026 Outlook Might Change The Case For Investing In Kiniksa (KNSA) - simplywall.st

KNSA Looks 59.8% Overvalued on GF Value™ After Q2 Earnings Surge - GuruFocus

KNSA Looks 58.0% Overvalued on GF Value™ as Shares Surge 22.7% - GuruFocus

KNSA Looks 59.0% Overvalued on GF Value™ as Shares Surge Amid Mi - GuruFocus

Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $99 From $72, Maintains Outperform Rating - marketscreener.com

Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights - Yahoo Finance

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week HighWhat's Next? - MarketBeat

KNSA: Record ARCALYST sales and strong pipeline progress drove raised 2026 guidance and cash growth - TradingView

Kiniksa Pharmaceuticals International, plc Provides Earnings Guidance for Year 2026 - marketscreener.com

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates - Yahoo Finance

KNSA: Q2 2026 delivered 55% YoY ARCALYST sales growth and raised 2026 revenue guidance to $980–$995M - TradingView

Is Kiniksa Pharmaceuticals (KNSA) Overvalued After Q2 Earnings B - GuruFocus

Kiniksa Pharmaceuticals International (KNSA) Reports Q2 2026 Numbers - AlphaStreet

Kiniksa Pharmaceuticals stock rises 2% on raised guidance, revenue beat By Investing.com - Investing.com Nigeria

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.28 - marketscreener.com

Rubric Capital Management LP Acquires 421,347 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Kiniksa (Nasdaq: KNSA) boosts 2026 ARCALYST sales view after strong Q2 - Stock Titan

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution - GlobeNewswire

Kiniksa Pharmaceuticals Announces Q2 2026 Financial Results and Advances Clinical Pipeline Developments - Kalkine Media

KNSA|Kiniksa Pharmaceuticals International PLC|Price:63.560|Chg%:+0.720 - TradingKey

Kiniksa Pharmaceuticals International PLC (KNSA) Cash Flow - TradingKey

Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2026: Everything You Need To Know Ahead Of ... - Yahoo Finance

Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2026: Everyt - GuruFocus

Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High-Growth Stock with Strong Technical Setup - ChartMill

KNSA|Kiniksa Pharmaceuticals International PLC|Price:62.840|Chg%:-0.210 - TradingKey

Kiniksa Pharmaceuticals International PLC - TradingKey

Kiniksa Pharmaceuticals International PLC (KNSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Kiniksa Pharmaceuticals International PLC (KNSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Kiniksa Pharmaceuticals International PLC (KNSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Kiniksa Pharmaceuticals International PLC (KNSA) Income Statement - TradingKey

TradingKey - TradingKey

Granahan Investment Management LLC Cuts Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Spruce Street Capital LP Has $36.65 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Kiniksa Pharmaceuticals International, plc Revenue Breakdown – NASDAQ:KNSA - TradingView

Zacks.com featured highlights include American Outdoor Brands, Cimpress, National Energy Services Reunited, CTO Realty Growth and Kiniksa Pharmaceuticals International - The Globe and Mail

Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a shareEarnings Preview - TradingView

Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High Growth Momentum Stock With a Breakout Setup - ChartMill

Kiniksa Pharmaceuticals to report Q2 2026 results in conference call and webcast - Bitget

Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 - The Manila Times

Kiniksa to discuss portfolio execution in July 28 webcast - Stock Titan

ALKS

$49.85

1.61%

RDY

$12.11

1.30%

ELAN

$23.61

0.25%

NBIX

$154.49

1.16%

VTRS

$16.23

0.00%

UTHR

$508.48

1.75%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く